Herman Krapf
Vorstandsvorsitzender bei Eribis Pharmaceuticals AB
Profil
Herman Krapf is the founder and Chief Executive Officer of Eribis Pharmaceuticals AB, a company founded in 2006.
He also held former positions as Manager-Marketing, Sales & Business Development at International Business Machines Corp., Pharmacia Biotech AB, and Helax AB.
Additionally, he served as Principal at LipoCore AB.
Aktive Positionen von Herman Krapf
| Unternehmen | Position | Beginn |
|---|---|---|
Eribis Pharmaceuticals AB
 Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Vorstandsvorsitzender | 01.01.2006 |
Ehemalige bekannte Positionen von Herman Krapf
| Unternehmen | Position | Ende |
|---|---|---|
| LipoCore AB | Corporate Officer/Principal | - |
Helax AB
 Helax AB Medical SpecialtiesHealth Technology Part of Sotera Health Co., Helax AB is a Swedish company that provides products for radiation-based cancer treatment. The company is based in Uppsala, Sweden. The company was founded by Hans Erik Dahlin. Helax was acquired by Nordion (Canada), Inc., part of Sotera Health Co. from July 30, 2018 on May 04, 1999. | Vertrieb & Marketing | - |
| IBM | Vertrieb & Marketing | - |
| Pharmacia Biotech AB | Vertrieb & Marketing | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IBM | Technology Services |
| Private Unternehmen | 4 |
|---|---|
Eribis Pharmaceuticals AB
Eribis Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage. | Health Technology |
| Pharmacia Biotech AB | Health Technology |
Helax AB
Helax AB Medical SpecialtiesHealth Technology Part of Sotera Health Co., Helax AB is a Swedish company that provides products for radiation-based cancer treatment. The company is based in Uppsala, Sweden. The company was founded by Hans Erik Dahlin. Helax was acquired by Nordion (Canada), Inc., part of Sotera Health Co. from July 30, 2018 on May 04, 1999. | Health Technology |
| LipoCore AB |
